(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of 76.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.59%.
Invivyd's revenue in 2026 is $53,426,000.On average, 6 Wall Street analysts forecast IVVD's revenue for 2026 to be $36,759,922,348, with the lowest IVVD revenue forecast at $17,752,035,686, and the highest IVVD revenue forecast at $78,456,774,612. On average, 6 Wall Street analysts forecast IVVD's revenue for 2027 to be $46,096,852,194, with the lowest IVVD revenue forecast at $14,677,970,224, and the highest IVVD revenue forecast at $105,656,517,279.
In 2028, IVVD is forecast to generate $90,255,104,548 in revenue, with the lowest revenue forecast at $49,018,881,692 and the highest revenue forecast at $133,390,363,983.